TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
ATLANTA, Feb. 29, 2016 -- Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the 36th Annual Cowen Healthcare Conference, to be held March 7-9, 2016 at the The Boston Marriott Copley Place, Boston, Massachusetts. Alimera Sciences' presentation will take place Wednesday, March 9, 2016 at 8:00 AM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Relations" section of the Company's website at www.alimerasciences.com. A replay of the conference presentation will also be available.
About Alimera Sciences
Alimera Sciences (NASDAQ:ALIM) (Alimera), founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases.
For more information, please visit www.alimerasciences.com.
COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
